Home Journals Articles Updates About
CN
image
收藏切换
Clinical research status of PCSK9 inhibitors
收藏切换
PDF
Yan-rong FENG1, Xiao-yu LIU2, Tian HAO1, Rui DONG1, Cen-yu WANG1, Jing-hong ZHANG1, Qi CHEN3
Chinese Journal of Clinical Pharmacology | 2025, 41(7) : 1044 - 1050
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(7): 1044-1050
• Review •
Clinical research status of PCSK9 inhibitors
Full
Yan-rong FENG1, Xiao-yu LIU2, Tian HAO1, Rui DONG1, Cen-yu WANG1, Jing-hong ZHANG1, Qi CHEN3
Affiliations
  • 1.First Clinical Medical College, Inner Mongolia Medical University, Hohhot 010020, Inner Mongolia Autonomous Region, China
  • 2.Department of Cardiovascular Medicine, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010030, Inner Mongolia Autonomous Region, China
  • 3.Third Clinical Medical College, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Published: 2025-04-17 doi: 10.13699/j.cnki.1001-6821.2025.07.026
Outline
收藏切换

Low density lipoprotein cholesterol (LDL-C) is a pathogenic risk factor for atherosclerotic cardiovascular disease (ASCVD), so domestic and international guidelines recommend strict management of its level. Statins are the cornerstone of lipid-lowering therapy, however, some patients are still unable to achieve LDL-C target with moderate doses of statins. There is a 6% effect of statins, so combination with a novel lipid-lowering drugs is needed. Proprotein convertase chymotrypsin 9 (PCSK9) inhibitors are currently novel lipid-lowering drugs, which further reduce LDL-C levels in plasma by lowering the level or inhibiting the function of PCSK9 in vivo, thus playing a role in regulating blood lipids and reversing atherosclerotic plaques. The PCSK9 inhibitors currently used in clinical application in China include eloeu monoclonal antibody, aliskiren monoclonal antibody and inksilan, etc. This article briefly describes the classification of PCSK9 inhibitors and related clinical studies and summarizes the current research status of PCSK9 inhibitors in regulating blood lipids and affecting atherosclerotic plaques.

alirocumab  /  evolocumab  /  inclisiran  /  proprotein convertase subtilisin kexin 9 inhibitor  /  low density lipoprotein cholesterol
Yan-rong FENG, Xiao-yu LIU, Tian HAO, Rui DONG, Cen-yu WANG, Jing-hong ZHANG, Qi CHEN. Clinical research status of PCSK9 inhibitors[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (7) : 1044 -1050 . DOI: 10.13699/j.cnki.1001-6821.2025.07.026
Appendix
Less
Year 2025 volume 41 Issue 7
PDF
1
0
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.07.026
  • Receive Date：2024-10-27
  • Online Date：2026-08-04
  • Published：2025-04-17
Article Data
Affiliations
History
  • Received：2024-10-27
Funding
Affiliations
    1.First Clinical Medical College, Inner Mongolia Medical University, Hohhot 010020, Inner Mongolia Autonomous Region, China
    2.Department of Cardiovascular Medicine, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010030, Inner Mongolia Autonomous Region, China
    3.Third Clinical Medical College, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.07.026
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House